
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The granulomatosis with polyangiitis treatment market is expected to grow at a CAGR of 4.90% during the forecast period of 2025-2034, driven by increased clinical trials and research to develop novel therapies and improve existing treatment options, enhanced disease recognition and management, and growing regulatory support across the 8 major markets.
Base Year
Historical Period
Forecast Period
The incidence of granulomatosis with polyangiitis tends to increase with age, with a peak incidence in older adults occurring between the ages of 64 to 75 years. Thus, the growing aging population is expected to drive market demand for effective treatments.
One of the major market trends is the surge in clinical research activities aimed at improving existing treatment protocols.
The market share is influenced by the growing regulatory support. Incentives offered by the health regulatory bodies encourage pharmaceutical companies to invest in rare disease treatments including granulomatosis with polyangiitis.
Compound Annual Growth Rate
4.9%
Value in
2025-2034
Granulomatosis with Polyangiitis Treatment Market Outlook
*this image is indicative*
Granulomatosis with polyangiitis is a medical condition that causes inflammation of blood vessels. The body parts affected by this disease include ears, nose, and kidney, among others. This disease is prevalent among children, adults, and geriatrics and causes severe symptoms such as chest pain, tiredness, nosebleeds, loss of appetite, and weight loss.
The granulomatosis with polyangiitis treatment market is witnessing an increase in the research and development activities by major biopharmaceutical companies. Key market players are actively investing in developing effective therapeutics to counter this disorder which is likely to lead to improved medications. Moreover, the market is anticipated to be aided by advanced X-rays, CT scans, and MRI in modern hospitals which is bolstering the diagnosis process for timely treatment of this condition. Furthermore, the market is likely to be navigated by the increasing geriatric population, coupled with the favorable reimbursement policies of the government.
Increasing Elderly Population to Affect the Market Landscape Significantly
The prevalence of this rare vasculitis affecting small vessels is estimated between 1/6,400 - 42,000 with the incidence ranging between 1/84,000-475,000 every year. Recent data reveals that childhood-onset disease shows female predominance whereas a slight male predominance characterizes adult-onset. Among the anti-neutrophil-cytoplasmic-antibody (ANCA) associated vasculitides (AAV), granulomatosis with polyangiitis is considered as the most common type. The incidence rate is reported to be higher in adults compared to the pediatric age group with a peak incidence at 64 to 75 years of age. Since the prevalence of this autoimmune disease tends to increase with age, the growing aging population is expected to influence the market demand for effective treatments.
Growth in Clinical Trials to Meet Rising Granulomatosis with Polyangiitis Treatment Market Demand
There is a growing number of clinical trials and research activities focused on exploring new treatment strategies and drug combinations to manage granulomatosis with polyangiitis. For instance, a study published in JAMA Network Open suggested that granulomatosis with polyangiitis patients, if treated with rituximab compared to cyclophosphamide for induction therapy, are more likely to show achievement of remission. Such findings are set to influence clinical decision-making and guidelines associated with the choice of remission-inducing regimen for patients with GPA. Thus, the surge in clinical research activities is anticipated to improve existing treatment protocols and augment market demand in the forecast period.
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
The EMR’s report titled “Granulomatosis with Polyangiitis Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Mode of Purchase
Market Breakup by Gender
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on Drug Type is Anticipated to Witness Substantial Growth
Based on the drug type, the market is segmented into steroids (prednisolone, dexamethasone, and others) and immunosuppressants (cyclosporine, tacrolimus, sirolimus), among others. Immunosuppressants for the treatment of granulomatosis with polyangiitis are gaining traction in the healthcare industry, owing to the high response rate of this medication. Immunosuppressants such as cyclophosphamide with prednisone are widely used in the treatment of this disease as they pose a lesser chance of fatality during the treatment.
Such immunosuppressants are consumed orally which is a major advantage of this medication amidst the changing patient preference towards minimally invasive treatment procedures. Methotrexate and azathioprine are some other examples of immunosuppressants that calm down the immune system of the body, thereby, keeping the disease under control. Therefore, the anticipated increase in the demand for immunosuppressants are likely to aid the segment’s growth in the coming years.
The segmentation based on the region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Countries such as the United States are high healthcare spenders globally. The regulations of the government encouraging the development of therapeutics and diffusing knowledge about this disorder are propelling the market growth. In addition to this, the growing FDA approvals of immunosuppressants and drugs are further expanding the opportunities for this treatment market.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
This American biotechnology corporation, operating as an independent subsidiary under its parent organization Roche Holding AG, is one of the leading market players. Its FDA-approved Rituxan® (rituximab) is commonly used to adult patients with granulomatosis with polyangiitis.
Global biopharma company GlaxoSmithKline plc. significantly contributes the granulomatosis with polyangiitis treatment market growth by investing heavily in R&D to bring new treatments for autoimmune diseases to market.
Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. has a prominent presence in the market and is known for its TRUXIMA® (rituximab-abbs) injection, a biosimilar of Rituxan® (rituximab), for the treatment of granulomatosis with polyangiitis.
This global biopharmaceutical company is engaged in the development of innovative treatments for several autoimmune diseases. The key product of the company includes RUXIENCE® (rituximab-pvvr) injection which is indicated for granulomatosis with polyangiitis in adult patients in combination with glucocorticoids.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Actiza Pharma, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceutical, Inc., Novartis AG, and Sanofi.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2024 |
Historical Period | 2018-2024 |
Forecast Period | 2025-2034 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Type |
|
Breakup by Route of Administration |
|
Breakup by Mode of Purchase |
|
Breakup by Gender |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.